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Abstract
Background: Currently, there are no satisfactory biomarkers available to screen for diffuse large
B cell lymphoma (DLBCL) or to identify patients who do not benefit from standard anti-cancer
therapies. In this study, we used serum proteomic mass spectra to identify potential serum
biomarkers and biomarker patterns for detecting DLBCL and patient responses to therapy.
Methods: The proteomic spectra of crude sera from 132 patients with DLBCL and 75 controls
were performed by SELDI-TOF-MS and analyzed by Biomarker Patterns Software.
Results: Nine peaks were considered as potential DLBCL discriminatory biomarkers. Four peaks
were considered as biomarkers for predicting the patient response to standard therapy. The
proteomic patterns achieved a sensitivity of 94% and a specificity of 94% for detecting DLBCL
samples in the test set of 85 samples, and achieved a sensitivity of 94% and a specificity of 92% for
detecting poor prognosis patients in the test set of 66 samples.
Conclusion: These proteomic patterns and potential biomarkers are hoped to be useful in clinical
applications for detecting DLBCL patients and predicting the response to therapy.
Background
Diffuse large B-cell lymphoma (DLBCL), the most com-
mon subtype of non-Hodgkin lymphoma (NHL) in
adults, is a potentially curable disease. Nonetheless, with
currently available treatment options, long-term remis-
sion can only be achieved in about 50% of all diagnosed
patients. Detecting cancers at their earliest stages will
result in higher rates for curing the disease [1,2]. The
application of new technologies for the earlier detection
of DLBCL could have an important effect on public
health, and to achieve this goal, specific and sensitive
molecular markers are essential.
Each organ and tissue perfused by blood can contribute to
modify or remove circulating proteins and peptides. Con-
sequently, the serum proteome may reflect the abnormal-
ity or pathologic state of organs and tissues [3]. By using
surface enhanced laser desorption/ionization time-of-
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flight mass spectrometry (SELDI-TOF-MS), Liotta et al. [4]
identified proteomic patterns in serum that distinguished
neoplastic disease from non-neoplastic disease within the
ovary. This result yielded a sensitivity of 100%, a specifi-
city of 95%, and a positive predictive value of 94%.
Another study showed that the proteomic pattern cor-
rectly predicted 36 (95%; 95% confidence interval [CI] =
82–99%) of 38 patients with prostate cancer, while 177
(78%) of 228 patients were correctly classified as having
benign conditions. For men with marginally elevated PSA
levels, the specificity was 71% [3]. Other groups also used
this approach successfully to diagnose ovarian, prostate
[5-7], and breast cancers [8-10]. Mauvieux et al.[11] iden-
tified and characterized markers of interest in chronic B-
cell malignancies. This study emphasized the usefulness
of mass spectrometry studies in such malignancies. Lin et
al.[12] identified proteins that may be involved in FL pro-
gression using SELDI. They rapidly identified a number of
potential candidate proteins with specific regard to FL
transformation. Their studies demonstrate the utility of
SELDI-TOF-MS for the rapid discovery of differentially
expressed proteins using femtomolar quantities of crude
protein derived from biopsy material.
Although DLBCL is a curable disease, fewer than one-half
of all diagnosed patients are cured with conventional
chemotherapy. It is necessary to identify patients who do
not benefit from standard treatment and should receive
risk-adjusted therapies [13]. In 1993, the international
prognostic index (IPI; age, performance status, stage,
number of extranodal sites, and serum lactate dehydroge-
nase [LDH]) was proposed based on overall survival rates
of 2031 adults of all ages with aggressive lymphomas who
were treated in the United States, Canada, and Europe
with doxorubicin-based chemotherapy with or without
involved-field radiotherapy [14]. This system can be used
to determine treatment and allow results to be compared
among centers. IPI is the current gold standard parameter
of prediction and it is mainly a clinical prognostic model
developed to identify DLBCL patients who are unlikely to
be cured with standard therapy. However, IPI is imperfect
in its identification of high-risk patients for the intrinsic
molecular heterogeneity in this disease [15]. Therefore, it
is important to find serum biomarkers for distinguishing
between good prognosis groups and poor prognosis
groups. SELDI-TOF-MS is one of the currently used tech-
niques to identify cancer biomarkers. SELDI profiling has
been used successfully to differentiate ovarian, breast,
prostate, and liver cancers from controls [9,10,16,17].
The aim of this study was to explore the application of
serum SELDI proteomic patterns for distinguishing
DLBCL patients from healthy individuals and distinguish-
ing good prognosis patients from poor prognosis patients.
Methods
Patients and samples
Serum samples were collected from the Bank of Tumor
Resource of patients, with prior consent from the donors,
at the Cancer Center of Sun Yat-sen University. Diagnoses
were confirmed by pathology and serum specimens were
obtained before treatment. The study was approved by the
Research Ethics Committee of the Cancer Center at Sun
Yat-sen University. This study included 207 specimens,
132 samples of which were obtained from DLBCL
patients and 75 samples which were from healthy individ-
uals in the Cancer Center of Sun Yat-sen University during
routine examinations.
The samples were separated into two groups during the
process of detecting DLBCL. The training group consisted
of 80 patients and 42 controls and the test group had 52
patients and 33 controls. The median age of the healthy
controls was 45 years (range, 23–73 years). The median
age of the cancer group patients was 52 years (range, 21–
72 years). The clinical stage distribution of the 132
patients was as follows: stage I (n = 16); stage II (n = 56);
stage III (n = 44); and stage IV (n = 16). There were 26
patients with an IPI of 0, 30 with an IPI of 1, 24 with an
IPI of 2, 37 with an IPI of 3, and 15 with an IPI of 4.
The next level of categorization included the 132 DLBCL
specimens in the study of the BPS (Biomarker Pattern soft-
ware) algorithm to discriminate the poor prognosis group
from the good prognosis group. The follow-up period
from diagnosis was 36 to 48 months. Patients alive for
more than 36 months from the time of diagnosis were
classified as the good prognosis group and patients alive
less than 36 months from the time of diagnosis were clas-
sified as the poor prognosis group. Eighty-three samples
were obtained from the good prognosis patients and 49
samples were from the poor prognosis patients. The spec-
imens were separated into two groups: 1) the training
group, with 33 good prognosis patients and 33 poor prog-
nosis patients and 2) the testing group with 50 good prog-
nosis patients and 16 poor prognosis patients.
The next study was performed to discriminate the relapse
group from the non-relapse group. Patients who relapsed
for less than 36 months from the time of diagnosis were
classified into the relapse group and patients who did not
were classified into the poor prognosis group; 62 non-
relapse patients and 70 relapse patients were included.
The specimens were separated into two groups: 1) the
training group with 33 non-relapse patients and 33 non-
relapse patients and 2) the testing group with 29 non-
relapse patients and 37 relapse patients.BMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
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All blood samples were obtained in the morning before
food intake, aliquoted into 40 μl specimens, and stored at
-80°C prior to running the assays.
Proteomics Data Set
The protocol reported by Adam et al. (2002) which was
used to classify SELDI-TOF MS spectra from 207 samples,
was followed. In brief, 10 μl of each serum sample and 90
μl of a solution containing 0.5% CHAPS (Sigma, Inc., St.
Louis, MO, USA) in phosphate-buffered saline (pH 7.4)
were added to each well of a 96-well plate. The mixture
was vortex-mixed at 4°C for 15 min, followed by the addi-
tion of 100 μl of Cibacron Blue 3GA (Sigma; prepared and
balanced in 0.5% CHAPS three times). The plates were
placed on a platform shaker at 4°C for 60 min. After cen-
trifugation, the supernatant (40 μl) was then transferred
onto the WCX2 chips so that each chip (8-spot format)
held four tumorous and four healthy samples to rule out
systematic error. All samples, including the training set,
test set, and normal serum quality control (QC) sample
were positioned randomly on the chips. The chips were
placed in a bioprocessor (Ciphergen Biosystems, Inc.),
which holds 12 chips and allows a larger volume of serum
to be applied to each chip array. The samples were
allowed to react with the surface of the WCX2 chip for 60
min at room temperature. The chips were then washed
three times by gently shaking on a platform shaker at a
speed of 700 rpm for 5 min with 200 μl of 20 mmol/L
HEPES (pH 7.4), air dried, and crystallized by the addi-
tion of α-cyano-4-hydroxycinnamic acid (CHCA; Cipher-
gen Biosystems, Inc.). The chips were read on a protein
biological system II (PBS-II) and a mass spectrometer
reader (Ciphergen Biosystems, Inc.). The data were col-
lected by averaging 140 laser shots with an intensity of
150, a detector sensitivity of 6, a peak mass of 30,000 Da,
and an optimized range of 2,000–20,000 Da. The mass
accuracy was calibrated to < 0.1% using the All-in-1 Pep-
tide Molecular Mass Standard (Ciphergen Biosystems,
Inc.). Each spectrum was composed of peak amplitude
measurements at approximately 15,200 points, defined
by a corresponding mass-to-charge ratio (M/Z) value.
Bioinformatics and Biostatistics
Using Biomarker Wizard software (Ciphergen Biosystems,
Inc.), we compiled all spectra. The qualified mass peaks
(signal-to-noise ratio > 5) with a M/Z between 2000 and
20,000 were detected automatically. The peak clusters
were completed with second-pass peak selection (signal-
to-noise ratio > 2 within a 0.3% mass window), and the
estimated peaks were added. The peak intensities were
normalized to the total ion current of the M/Zbetween
2000 and 20,000 using Protein-Chip software, version 3.0
(Ciphergen Biosystems, Inc.).
Decision tree classification
Construction of the decision tree classification algorithm
was performed by Ciphergen Biomarker Pattern software,
version 5.0. The classification tree split the data into two
nodes, using one rule at a time, to form peak intensities.
The splitting decisions in this case were based on the nor-
malized intensity levels of the peaks from the SELDI pro-
tein expression profile. The process of splitting was
continued until the terminal nodes were produced. After
performing the V-fold cross validation 50, the accuracy of
each classification tree was challenged with the blinded
testing set.
Statistical Analysis
A Bayesian approach was used to calculate the expected
probabilities of each class in each terminal node. Compar-
ison of relative peak intensity levels between groups was
made using the Student's t test and in all cases, P < 0.05
was considered statistically significant. Specificity was cal-
culated as the ratio of the number of non-cancer samples,
good prognosis samples, or non-relapse samples correctly
classified to the total number of non-cancer samples,
good prognosis samples, or non-relapse samples, respec-
tively. Sensitivity was calculated at the ratio of the number
of correctly classified DLBCL samples, poor prognosis
samples, or relapse patients to the total number of DLBCL
samples, poor prognosis samples, or relapse samples.
Results
Identification of specific serum proteomic features
A total of four chip chemistries (hydrophobic surface,
immobilized metal affinity capture, weak cation exchange
[WCX], and strong anion exchange) were evaluated to
investigate which provided the best serum profile. Our
determinations revealed that the WCX chip provided the
most discriminating pattern for constructing a decision
tree.
Serum samples (n = 122; 42 controls and 80 cancers) in
the training set were assayed by SELDI mass spectrometry.
Another 85 samples (33 controls and 52 cancers) were
selected for the blinded test set for the algorithm. The
SELDI technology was particularly effective in resolving
the low molecular weight (< 20 kDa) proteins and
polypeptides. Peaks with a M/Z < 2 kDa were comprised
mainly of ion noise from the matrix and were therefore
excluded. Nine top-scored peaks (P < 0.01) at M/Zs of
2821, 2954, 3266, 4779, 5638, 5707, 5838, 5907, and
7975 were selected for analysis (Table 1). For separating
the groups, the sensitivity was from 62% to 84% and spe-
cificity was from 73% to 85%. These nine representative
peaks were higher in the tumor samples compared with
the controls and considered to be potential biomarkers
for discriminating DLBCL patients from non-cancerous
patients. These representative spectra were shown in theBMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
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Additional file 1, which showed nine protein biomarkers
in serum for detection of DLBCL.
Of the 132 DLBCL serum samples, 66 samples, including
33 good prognosis samples and 33 poor prognosis sam-
ples, were chosen randomly for the learning set and 66
samples, including 50 good prognosis samples and 16
poor prognosis samples, were selected for the blinded test
set, respectively. Four top-scored peaks (P < 0.05), at M/Zs
of 4078, 4304, 5481, and 8608 were selected as potential
discriminatory biomarkers for the good prognosis and
poor prognosis cases (Table 2). For separating the groups,
the sensitivity was from 61% to 80% and specificity was
from 65% to 88%. All four peaks were higher in the good
prognosis patients than in the poor prognosis patients.
Five peaks at M/Zs of 2954, 4304, 4320, 5069, and 16093
were chosen for potential biomarkers for discriminating
relapse patients from non-relapse patients (Table 3). Four
peaks at M/Zs of 4304, 4320, 5069, and 16093 were
higher in the non-relapse patients than in the relapse
patients. For separating the groups, the sensitivity was
from 60% to 74% and specificity was from 59% to 76%.
Decision tree construction
Breiman  et al. developed a decision tree (DT) model,
which uses a variant of the classification and regression
tree (CART) method. This method consists of two steps:
1) tree construction and 2) tree pruning [18,19]. In the
tree construction process, the best predictor variables were
identified with algorithms that divided the parent node
sample into two child nodes. The decision tree classifies a
particular pattern through a sequence of questions, begin-
ning at the root node, and formulates the subsequent
questions based upon the initial answers. This process is
repeated until a terminal node is attained. At the end of
the process, each terminal node contains a certain per-
centage of tumor samples. This percentage specifies the
probability of a sample as being tumorous. If a terminal
node contains the proportion of tumor sample, (p) > 50%
(i.e., p > 0.5), then all the samples in this terminal are des-
ignated as tumor samples, and p is the probability value
assigned to the entire sample in this terminal node. Simi-
larly, samples are non-tumorous if the probability is < 0.5.
Seven peaks at 2091, 2503, 3960, 4872, 5251, 5814, and
14,133 Da were selected by the BPS algorithm to discrim-
inate DLBCL samples from control samples. Figure 1 illus-
trates the decision tree that was generated from the
learning set to classify the two groups. The classification
algorithm correctly predicted 98 % (41 of 42) and 99 %
(79 of 80) of the samples from the control and the DLBCL
groups, respectively. Analyses of the spectra from the 85
testing samples showed that the classification algorithm
correctly predicted 94% (80 of 85) of all of the samples,
with 94% (49 of 52) of DLBCL samples and 94% (31 of
33) of the control samples. The specificity was 94% and
the sensitivity was 94%. Most importantly, 16 cases of
stage I patients were all identified correctly (Table 4). The
representative spectra in the decision tree for the selected
diagnostic peaks were shown in the Additional file 2,
which showed seven serum peaks in mass pattern for diag-
nosis of SELDI.
Table 1: Proteomic features showing significantly differences in expression by ProteinChip in detection of DLBCL.
Mass(Da) p Ctrl(mean) Ctrl(SD) Tumor(mean) Tumor(SD) Fold
2821.906 5.02E-06 2.614971 1.582986 4.566231 2.535257 1.746188
2954.257 5.51E-06 1.308963 0.767800 2.965317 1.236755 2.265394
3266.786 3.45E-07 1.218587 0.894500 2.726363 1.368996 2.237315
4779.803 6.56E-05 0.948255 0.563501 2.007074 1.242644 2.116597
5638.932 3.56E-06 21.96427 6.529237 40.96807 12.88758 1.865215
5707.424 1.32E-06 1.697549 0.592136 3.525848 0.978960 2.077023
5838.342 8.04E-07 2.149179 1.109202 4.132974 1.782941 1.923048
5907.698 4.44E-06 4.715597 2.001269 14.39084 4.695559 3.051754
7975.704 0.025325 4.392209 3.298483 10.10014 3.349020 2.299559
DLBCL: Diffuse large B-cell lymphomas; Mean and SD refer to the peak intensities
Table 2: Proteomic features showing differences in prediction of response to therapy by ProteinChip in DLBCL patients.
Mass(Da) p GP(mean) GP(SD) PP(mean) PP (SD) Fold
4078.883 0.01478 4.453288 2.181249 2.785609 1.187186 1.598677
4304.084 0.006578 8.614694 2.94989 3.437385 1.374539 2.506176
5481.569 0.018384 5.328566 2.653169 3.256677 1.239096 1.636197
8608.812 0.01478 4.453288 1.681249 2.785609 1.187186 1.598677
GP: Good prognosis; PP: Poor prognosis; Mean and SD refer to the peak intensities.BMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
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To discriminate the poor prognosis group from the good
prognosis group, four peaks at 4448, 5276, 5482, and
6394 Da were chosen by the BPS algorithm. The decision
tree to classify the two groups is shown in Figure 2. In the
training set, the classification algorithm correctly pre-
dicted 100% of the samples from the good prognosis
group and 100% of the samples from the poor prognosis
group. Analyses of the spectra in the test set showed that
the classification algorithm correctly predicted 92 % (61
of 66) of all of the samples with 92 % (46 of 50) of the
good prognosis group and 94 % (15 of 16) of the poor
prognosis group. The specificity was 92 % and the sensi-
tivity was 94 %.
Four peaks at 1950, 3960, 4304, and 5211 Da were cho-
sen for patterns to discriminate the relapse group from the
non-relapse group. Figure 3 showes the decision tree to
classify these two groups. In the training set, the classifica-
tion algorithm correctly predicted 100% of the samples
for the non-relapse group and 100% of the samples for
the relapse group. In the testing analyses, the classification
algorithm correctly predicted 91% (60 of 66) of all of the
samples with 90% (26 of 29) of the non-relapse group
and 92% (34 of 37) of the relapse group. The specificity
was 90% and the sensitivity was 92%.
Reproducibility and precision
To assess the precision and the accuracy of the proteomic
data in our analyses, we employed external calibration
standards using the All-in-1 Peptide Molecular Mass
Standard (Ciphergen Biosystems, Inc.), which allowed us
to achieve a mass accuracy of approximately 1 Da in
10,000. To confirm the reproducibility of SELDI spectra in
our study, namely, the intensity from array-to-array on a
single chip (intra-assay) and between chips (inter-assay)
was determined using the pooled normal serum quality
control (QC) sample. Ten selected M/Z peaks were ran-
domly selected and compared to calculate the coefficient
of variance. The intra-assay analyses were performed in
triplicate and the inter-assay analyses were performed on
three different days. The intra- and inter-assay mean CV
for the normalized intensity were 10% and 14%, respec-
tively.
IPI
The IPI was defined as a positive criterion to identify
DLBCL patients who are unlikely to be cured with stand-
ard therapy. Patients were grouped into two subgroups: 1)
an IPI of 0–2 and 2) an IPI of 3–4. Patients with an IPI of
0–2 were considered as patients with a good prognosis
and patients with an IPI of 3–4 were considered as
patients with a poor prognosis. For predicting DLBCL
patients with a poor prognosis, the sensitivity of IPI was
61% (30/49) and the specificity was 80% (66/83), while
the specificity of the SELDI classification model was 92 %
and the sensitivity was 94 %. The SELDI classification
model predicted the response significantly better than the
conventional IPI.
Discussion
For the majority of patients, DLBCL is a systemic disease at
the time of diagnosis. At the completion of the initial stag-
ing evaluation, stages II, III, or IV disease are documented
in approximately 75% of all DLBCL patients [2]. Thus, the
search for new early serum diagnostic markers of DLBCL
will be important for the detection of early stage DLBCL
Table 3: Proteomic features showing significantly differences in prediction of relapse by ProteinChip in DLBCL patients.
Mass(Da) p NR(mean) NR(SD) RE(mean) RE(SD) Fold
2954.992 0.041855 1.707398 0.795678 3.394241 1.859434 1.987961
4304.379 0.001273 9.265967 2.843153 4.905272 2.405961 0.529386
4320.266 0.030246 2.983608 1.15555 1.239195 0.72511 0.415334
5069.691 0.045795 2.972709 1.139147 1.282858 0.734228 0.431545
16093.56 0.043788 2.891461 1.049451 1.364795 0.534483 0.472009
NR: Non-relapse group; RE: Relapse group; PFS: Progression free survival; Mean and SD refer to the peak intensities.
Table 4: The sensitivity of the SELDI marker pattern in detecting different DLBCL stages.
Variables Clinical 
stages
n Correct cases Error cases Sensitivity (%) P value
I 16 16 0 100.00 <0.05
II 56 54 2 96.43 <0.05
III 44 40 4 90.91 <0.05
IV 16 15 1 93.75 <0.05
DLBCL: Diffuse large B-cell lymphomasBMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
Page 6 of 11
(page number not for citation purposes)
patients who have a longer survival rate. The recent devel-
opment of surface-enhanced laser desorption/ionization
technology, based on improved methods for the chemical
preparation of absorptive surfaces and their use for solid-
state mass spectrometry, allows high-throughput protein
analysis of crude biologic samples [16]. Using these tech-
niques in combination promises a working approach for
identifying potential DLBCL biomarkers for early-stage
diagnosis and treatment.
Low-molecular-weight serum protein profiling may reflect
the pathologic state of organs and aid in the early detection
of cancer. Furthermore, MALDI-TOF and SELDI-TOF mass
spectrometry can profile proteins in this range. These pro-
files can contain thousands of data points, necessitating
sophisticated analytical tools. Bioinformatics has been
used to study physiologic outcomes and cluster gene micro-
arrays [6].
The application of proteomics to the analysis of the human
prostate could potentially uncover useful biomarkers.
SELDI offers the advantages of rapid, high throughput
screening using small volumes of clinical samples, and
includes rapidity and reproducibility in the screening of
protein expression profiles (also known as 'phenomic fin-
gerprints'). However, there are no published data on the
use of this technique coupled with a decision tree algo-
rithm in studies of DLBCL protein profiles. In this study, we
demonstrated that SELDI profiling of serum significantly,
accurately, and reproducibly distinguished patients with
Diagram of decision tree analysis pattern of classification of DLBCL vs. normal samples Figure 1
Diagram of decision tree analysis pattern of classification of DLBCL vs. normal samples. The root node (top), 
descendant nodes and the terminal nodes (Node 1–Node 7) are shown as squares. N represents the number of samples. The 
first number under the root and descendant nodes is the mass value followed by the peak intensity value. For example, the 
mass value under the root node is 5814 Da, and the intensity is 0.967. DLBCL: Diffuse large B-cell lymphomas.BMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
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DLBCL from healthy controls. The pattern also had a sensi-
tivity of 100% for detecting stage I DLBCL patients, suggest-
ing that the pattern may be better suited for the early
detection of DLBCL. Similar to previous report that the
SELDI decision tree captured more of the "early" (grade I
and II) bladder cancer [20].
DLBCL is the most common type of NHL and accounts for
approximately one-third of the total number of adult NHL
patients. Although it represents a curable disease, fewer
than one-half of the patients are cured with conventional
chemotherapy. Identification of patients who do not bene-
fit from current treatment may constitute the basis for risk-
adjusted therapies for DLBCL. Therefore, it is important to
develop a method for identifying patients who may be can-
didates for investigational approaches, and to distinguish
high-risk patients from patients who benefit from the
standard therapy. The disease free survival (DFS) and over-
all survival (OS) are the best end-points for predicting the
prognosis of DLBCL patients. Three-year DFS and OS were
observed in our study. The decision tree to classify two
groups by the BPS algorithm correctly predicted that 92%
of all of the sampled cases who could or could not benefit
from the anti- DLBCL standard therapy.
Diagram of decision tree analysis pattern of classification of poor prognosis vs. good prognosis samples Figure 2
Diagram of decision tree analysis pattern of classification of poor prognosis vs. good prognosis samples. The 
root node (top), descendant nodes and the terminal nodes (Node 1–Node 4) are shown as squares. N represents the number 
of samples. The first number under the root and descendant nodes is the mass value followed by the peak intensity value. For 
example, the mass value under the root node is 5482 Da, and the intensity is 4.911.BMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
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However, the peaks in biomarkers and tree pattern were not
the same, which could be explained by the fact that biomar-
kers had been identified as a single peak which showed the
highest discrepancy between two groups, while the patterns
stressed synergistic effects of peaks in-group. Moreover,
peaks in the pattern still showed a significant difference in
two groups, but the degree of difference was less than those
in biomarkers.
However, in our study, the tree patterns from BPS indeed
showed higher sensitivity and specificity than single
biomarker or biomarker combination, they represented the
highest discrepancy between two groups and may be good
candidates for further protein identification analysis. Using
SELDI system to analyze the urine samples from transi-
tional cell carcinoma (TCC) from bladder and control sam-
ples, Vlahou et al.[21,22]identified several novel
biomarkers for TCC diagnosis. Their further works identi-
fied α-defensin as one of the biomarkers, and expression of
α-defensin peptides in bladder cancer cells increased with
tumor invasiveness. The above experiments paved the way
for further identification of single biomarker. In the future
Diagram of decision tree analysis pattern of classification of relapse vs. non-relapse samples Figure 3
Diagram of decision tree analysis pattern of classification of relapse vs. non-relapse samples. The root node (top), 
descendant nodes and the terminal nodes (Node 1–Node 4) are shown as squares. N represents the number of samples. The 
first number under the root and descendant nodes is the mass value followed by the peak intensity value. For example, the 
mass value under the root node is 4304 Da, and the intensity is 6.387.BMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
Page 9 of 11
(page number not for citation purposes)
we will broaden the number of samples to testify these
biomarkers and their combination.
The IPI, a clinical predictor for overall survival (OS), has
been the primary prognostic model used in the manage-
ment of patients with DLBCL. The subdivision of patients
according to the number of prognostic factors into low risk
(none or one factor), low-intermediate risk (two factors),
high-intermediate risk (three factors), or high risk (four or
five factors) with predicted 5-year OS values of 73%, 51%,
43%, and 26%, respectively, rapidly became the most
widely used and accepted prognostic model for intermedi-
ate-grade lymphoma [14]. However, in all the clinical mod-
els, including the IPI index, there was marked residual
heterogeneity in outcome, which was reflected by consider-
ably variable survival of patients with identical prognostic
scores. The latter was explained by the marked genetic and
molecular heterogeneity that underlies disease aggressive-
ness and tumor progression, and led to evaluation of
molecular and genetic markers associated with a patient's
survival. SELDI biomarker and patterns could complement
genetic and molecular heterogeneity which contribute to
poor prognosis [23]. In our study, patients with an IPI of 0–
2 were grouped together because they enjoyed dramatically
better progression-free, cause-specific, and overall survival
rates than those with an IPI of 3–4 [24]. Finally, the SELDI
classification model was significantly better than the con-
ventional IPI in the sensitivity and specificity of prediction.
There is a great need to discover novel biomarkers and
translate them into routine clinical use. However, initial
enthusiasm about these new technologies has been some-
what tempered by questions on method reproducibility. It
has been reported that serum proteomic patterns obtained
by the SELDI-TOF technique may not be reproducible and
that the discriminatory peaks are not consistent, either
within a group or among groups of investigators, for the
same type of cancer [25-27].
By analysis of the publicly available data posted by Petri-
coin and coworkers [3,4], Diamandis [28,29] raised major
concerns about the reproducibility of the SELDI-based
approaches, whereas the concerns raised by Sorace and
Zahn [30] and Baggerly et al.[31] was the bias of study
design. There is also a great deal of controversy as to
whether the use of high-throughput proteomic techniques,
such as SELDI, can improve the early detection of cancer.
The alternative hypothesis is that these differences between
cancer and control groups are not due to the presence of
cancer, but to something else. Possible confounders could
include: 1) variability in sample collection, processing, and
storage; 2) baseline characteristics of study subjects; 3)
inappropriate statistical design; and 4) variations in mass
spectrometer stability and protein chip performance. In
addition, it is not known whether proteomic patterns differ
between plasma and serum, or how they are influenced by
lipemia, icterus, the number of freeze/thaw cycles the sam-
ple underwent, the sample's length of storage, or the sub-
ject's menstrual cycle, nutritional status, or drug use [29].
However, several groups have reported good reproducibil-
ity by improving the sample preparation methods [32,33].
Diamandis [29] raised concern that the "discriminating
peaks are not consistent either within a group or among
groups of individuals." The report of Semmes may be help-
ful to reconsider the comments of Diamandis [29].
Semmes clearly showed that the same three diagnostic
peaks, at least the first strong diagnostic peak, were identi-
fied at multiple sites and were effective at differentiating
case/control samples at all sites. These results demonstrated
that the "between-laboratory" reproducibility of SELDI-
TOF-MS serum profiling approaches that of "within-labo-
ratory" reproducibility, as determined by measuring dis-
crete M/Z peaks over time and across laboratories [34].
The limitations do not inhibit the application of mass spec-
trometry as an analytic tool or to other proteomic
approaches used to identify proteins in serum or other bio-
logical fluids. Scientific skepticism and debate are essential
to the progress of science. Analysis of poor quality, noise-
laden protein expression profiles, however, will likely lead
to results lacking biological relevance. Therefore, quality
assessment of the protein expression profiles and determi-
nation of reproducibility of SELDI-TOF MS experiments
and profiles prior to data analysis is of critical importance
[34]. Low quality spectra should be identified and elimi-
nated from analysis to ensure the reliability of biomarkers
and the associated patterns discovered during analysis [35].
In our study, serum was collected in the morning before
food intake, which helped to avoid the effects of lipemia
and food. Serum was stored at -80°C and was not thawed
until analysis to evade protein instability due to freezing
and thawing. The pretreatment of serum followed the
standard methodology of several references and the man-
ual from Ciphergen Biosystems, Inc. Samples were ran-
domly added on the chips to shun bias. The proteomics
data set, decision tree classification, bioinformatic analysis,
and biostatistics were performed by software from Cipher-
gen Biosystems, Inc. (Biomarker Wizard software and
Ciphergen Biomarker Pattern software) according to sev-
eral references and standard manuals. The mass range from
2000 to 20,000 Da was selected for analysis because this
range contained the majority of the resolved protein/pep-
tides. The molecular masses from 0 to 2000 Da were elimi-
nated from analysis because this area contains adducts and
artifacts of the EAM and possibly other chemical contami-
nants. The intra- and inter-assay mean CV for the normal-
ized intensity in our study was below 15% and confirm the
reproducibility. We used a testing set (the blinded set) toBMC Cancer 2007, 7:235 http://www.biomedcentral.com/1471-2407/7/235
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testify peaks and patterns from the training test, which val-
idated the reproducibility. In the future, we will use another
set of samples to verify the results and confirm the repro-
ducibility.
The identity of the discriminating proteins by purification,
identification, and characterization is currently under
investigation. Revealing their identities will be essential for
understanding the biological role of these peptide/proteins
in the oncogenesis of DLBCL, potentially leading to novel
therapeutic targets. Moreover, identifying these protein
candidates will be essential for producing antibodies for
developing classical immunoassays, similar to the quanti-
tation techniques of PSA, prostate-specific membrane anti-
gens.
Conclusion
We found a proteomic archetype in serum that could dis-
tinguish DLBCL from non-tumorous control individuals
and discriminate the poor prognosis group from the good
prognosis group with high accuracy. The efficacy of screen-
ing early DLBCL and responsive patients would be
increased with these proteomic patterns.
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